Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;9(1):3–20. doi: 10.1111/j.1527-3458.2003.tb00241.x

SL651498, a GABAA Receptor Agonist with Subtype‐Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms

Guy Griebel 1,✉, Ghislaine Perrault 1, Jacques Simiand 1, Caroline Cohen 1, Patrick Granger 1, Henri Depoortere 1, Dominique Françon 1, Patrick Avenet 1, Hans Schoemaker 1, Yannick Evanno 1, Mireille Sevrin 1, Pascal George 1, Bernard Scatton 1
PMCID: PMC6741675  PMID: 12595909

ABSTRACT

SL651498 (6‐fluoro‐9‐methyl‐2‐phenyl‐4‐(pyrrolidin‐1‐yl‐carbonyl)‐2, 9‐dihydro‐1H‐pyrido[3,4‐b]indol‐1‐one) was identified as a drug development candidate from a research program designed to discover subtype‐selective GABAA receptor agonists for the treatment of generalized anxiety disorder and muscle spasms. The drug displays high affinity for rat native GABAA receptors containing α1 (K i= 6.8 nM) and α2 (K i= 12.3 nM) subunits, and weaker affinity for α5‐containing GABAA receptors (K i= 117 nM). Studies on recombinant rat GABAA receptors confirm these findings and indicate intermediate affinity for the α3β2γ2 subtype. SL651498 behaves as a full agonist at recombinant rat GABAA receptors containing α2 and α3 subunits, and as a partial agonist at recombinant GABAA receptors expressing α1 and α5 subunits. SL651498 produced anxiolytic‐like and skeletal muscle relaxant effects qualitatively similar to those of benzodiazepines (BZs) [minimal effective dose (MED): 1 to 10 mg/kg, i.p. and 3 to 10 mg/kg, p.o.]. However, unlike these latter drugs, SL651498 induced muscle weakness, ataxia or sedation at doses much higher than those having anxiolytic‐like activity (MED: 30 to 100 mg /kg, i.p. or p.o.). Moreover, in contrast to BZs, SL651498 did not produce tolerance to its anticonvulsant activity or physical dependence. It was much less active than BZs in potentiating the depressant effects of ethanol or impairing cognitive processes in rodents. The differential profile of SL651498 as compared to BZs may be related to its selective efficacy at the α2 and α3‐containing GABAA receptors. This suggests that selectively targeting GABAA receptor subtypes can lead to drugs with increased clinical specificity. SL651498 represents a promising alternative to agents currently used for the treatment of anxiety disorders and muscle spasms without the major side effects seen with classical BZs.

Keywords: Anxiety, Anxiolytic, Benzodiazepine, Diazepam, GABAA receptor, Muscle spasm, SL651498

Full Text

The Full Text of this article is available as a PDF (345.4 KB).

References

  • 1. Barnard EA, Skolnick P, Olsen RW, et al. International Union of Pharmacology. XV. Subtypes of γ‐aminobutyric acid A receptors: Classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998;50:291–313. [PubMed] [Google Scholar]
  • 2. Belzung C, Leguisquet AM, Griebel G. β‐CCT, a selective BZ‐ω1 receptor antagonist, blocks the anti‐anxiety but not the amnesic action of chlordiazepoxide in mice. Behav Pharmacol 2000;11:125–131. [DOI] [PubMed] [Google Scholar]
  • 3. Blanchard RJ, Blanchard DC. Anti‐predator defense as models of animal fear and anxiety In: Brain PF, Parmigiani S, Blanchard RJ, Mainardi D, Eds. Fear and Defence. London , UK : Harwood Academic Publishers, 1990;89–108. [Google Scholar]
  • 4. Boissier JR, Simon P, Aron C. A new method for the rapid screening of minor tranquillisers in mice. Eur J Pharmacol 1968;4:145–151. [DOI] [PubMed] [Google Scholar]
  • 5. Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high‐affinity [3H]diazepam binding. Proc Natl Acad Sci USA 1977;74:3805–3809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Cole SO. Effects of benzodiazepines on acquisition and performance: A critical assessment. Neurosci Biobehav Rev 1986;10:265–272. [DOI] [PubMed] [Google Scholar]
  • 7. Colpaert FC, Niemegeers CJ, Janssen PA. Theoretical and methodological considerations on drug discrimination learning. Psychopharmacologia 1976;46:169–177. [DOI] [PubMed] [Google Scholar]
  • 8. Cooper SJ, Kirkham TC, Estall LB. Pyrazoloquinolines: Second generation benzodiazepine receptor ligands have heterogeneous effects. Trends Pharmacol Sci 1987;3:180–184. [Google Scholar]
  • 9. Crestani F, Martin JR, Möhler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 2000;131:1251–1254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Davis M, Falls WA, Campeau S, Kim M. Fear‐potentiated startle: A neural and pharmacological analysis. Behav Brain Res 1993;58:175–198. [DOI] [PubMed] [Google Scholar]
  • 11. Depoortere H, Zivkovic B, Lloyd KG, et al. Zolpidem, a novel non‐benzodiazepine hypnotic: I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 1986;237:649–658. [PubMed] [Google Scholar]
  • 12. Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficits in rats and mice. J Am Pharm Assoc 1957;46:208–209. [DOI] [PubMed] [Google Scholar]
  • 13. Evanno Y, Sevrin M, Maloizel C, Le Galloudec O, George P. 1H‐pyrido[3,4‐b]indole‐4‐carboxamide derivatives, preparation and application thereof in therapeutics. WO9815552 1997.
  • 14. Fritschy JM, Weinmann O, Wenzel A, Benke D. Synapse‐specific localization of NMDA and GABAA receptor subunits revealed by antigen‐retrieval immunohistochemistry. J Comp Neurol 1998;390:194–210. [PubMed] [Google Scholar]
  • 15. Giusti P, Ducic I, Puia G, et al. Imidazenil: A new partial positive allosteric modulator of gamma‐aminobutyric acid (GABA) action at GABAA receptors. J Pharmacol Exp Ther 1993;266:1018–1028. [PubMed] [Google Scholar]
  • 16. Griebel G, Blanchard DC, Jung A, Blanchard RJ. A model of 'antipredator' defense in Swiss‐Webster mice: Effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 1995;6:732–745. [PubMed] [Google Scholar]
  • 17. Griebel G, Perrault G, Letang V, et al. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ(ω) receptor subtypes. Psychopharmacology 1999;146:205–213. [DOI] [PubMed] [Google Scholar]
  • 18. Griebel G, Perrault G, Sanger DJ. Subtype‐selective benzodiazepine receptor ligands In: Briley M, Nutt D, Eds. Anxiolytics. Basel : Birkhäuser, 2000;77–94. [Google Scholar]
  • 19. Griebel G, Perrault G, Simiand J, et al. SL651498: An anxioselective compound with functional selectivity for α2‐ and α3‐containing γ‐aminobutyric acidA (GABAA) receptors. J Pharmacol Exp Ther 2001;298:753–768. [PubMed] [Google Scholar]
  • 20. Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ. Comparison of the pharmacological properties of classical and novel BZ‐ω receptor ligands. Behav Pharmacol 1999;10:483–495. [DOI] [PubMed] [Google Scholar]
  • 21. Haefely W, Martin JR, Schoch P. Novel anxiolytics that acts as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 1990;11:452–456. [DOI] [PubMed] [Google Scholar]
  • 22. Haug T, Gotestam KG. Onset and offset of the diazepam stimulus complex. Pharmacol Biochem Behav 1982;17:1171–1174. [DOI] [PubMed] [Google Scholar]
  • 23. Hutchinson MA, Smith PF, Darlington CL. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. Prog Neurobiol 1996;49:73–97. [DOI] [PubMed] [Google Scholar]
  • 24. Irwin S, Kalsner S, Curtis A, Banuazizi A. Direct demonstration of consolidation of one‐trial learning. Fed Proc 1964;23:102. [Google Scholar]
  • 25. Jensen RA, Martinez JL, Vasquez BJ, McGaugh JL. Benzodiazepines alter acquisition and retention of an inhibitory avoidance response in mice. Psychopharmacology 1979;64:125–126. [DOI] [PubMed] [Google Scholar]
  • 26. Lader M. Benzodiazepines: A risk‐benefit profile. CNS Drugs 1994;1:377–387. [Google Scholar]
  • 27. Lecci A, Borsini F, Volterra G, Meli A. Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology 1990;101:255–261. [DOI] [PubMed] [Google Scholar]
  • 28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3–25. [DOI] [PubMed] [Google Scholar]
  • 29. Lister RG, Linnoila M. Alcohol, the chloride ionophore and endogenous ligands for benzodiazepine receptors. Neuropharmacology 1991;30:1435–1440. [DOI] [PubMed] [Google Scholar]
  • 30. Löscher W, Frey HH. Effect of convulsant and anticonvulsant agents on level and metabolism of gammaaminobutyric acid in mouse brain. Naunyn-Schmiedeberg's Arch Pharmacol 1977;296:263–269. [DOI] [PubMed] [Google Scholar]
  • 31. Low K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;290:131–134. [DOI] [PubMed] [Google Scholar]
  • 32. Mao CC, Guidotti A, Costa E. Evidence for an involvement of GABA in the mediation of the cerebellar cGMP decrease and the anticonvulsant action diazepam. Naunyn-Schmiedeberg's Arch Pharmacol 1975;289:369–378. [DOI] [PubMed] [Google Scholar]
  • 33. Martin JR, Pieri L, Bonetti EP, et al. Ro 16–6028: Anovel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry 1988;21:360–362. [DOI] [PubMed] [Google Scholar]
  • 34. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype. Nat Neurosci 2000;3:587–592. [DOI] [PubMed] [Google Scholar]
  • 35. Meyer OA, Tilson HA, Byrd WC, Riley MT. A method for the routine assessment of fore‐ and hindlimb grip strength of rats and mice. Neurobehav Toxicol 1979;1:233–236. [PubMed] [Google Scholar]
  • 36. Misslin R, Belzung C, Vogel E. Behavioural validation of a light/dark choice procedure for testing anti‐anxiety agents. Behav Process 1989;8:119–132. [DOI] [PubMed] [Google Scholar]
  • 37. Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300:2–8. [DOI] [PubMed] [Google Scholar]
  • 38. Möhler H, Okada T. Benzodiazepine receptor: Demonstration in the central nervous system. Science 1977;198:849–851. [DOI] [PubMed] [Google Scholar]
  • 39. Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982;297:681–683. [DOI] [PubMed] [Google Scholar]
  • 40. O'Donovan MC, Buckland PR, Spurlock G, McGuffin P. Bi‐directional changes in the levels of messenger RNAs encoding gamma‐aminobutyric acidA receptor alpha subunits after flurazepam treatment. Eur J Pharmacol 1992;226:335–341. [DOI] [PubMed] [Google Scholar]
  • 41. Parsons AM, Honda CN, Jia YP, et al. Spinal NK1 receptors contribute to the increased excitability of the nociceptive flexor reflex during persistent peripheral inflammation. Brain Res 1996;739:263–275. [DOI] [PubMed] [Google Scholar]
  • 42. Pellow S, Chopin P, File SE, Briley M. Validation of open: Closed arm entries in an elevated plus‐maze as a measure of anxiety in the rat. J Neurosci Meth 1985;14:149–167. [DOI] [PubMed] [Google Scholar]
  • 43. Perrault G, Morel E, Sanger DJ, Zivkovic B. Differences in pharmacological profiles of a new generation of benzodiazepine and non‐benzodiazepine hypnotics. Eur J Pharmacol 1990;187:487–494. [DOI] [PubMed] [Google Scholar]
  • 44. Perrault G, Morel E, Sanger DJ, Zivkovic B. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 1992;263:298–303. [PubMed] [Google Scholar]
  • 45. Perrault G, Morel E, Sanger DJ, Zivkovic B. Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence. Neuropharmacology 1993;32:855–863. [DOI] [PubMed] [Google Scholar]
  • 46. Puia G, Ducic I, Vicini S, Costa E. Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma‐aminobutyric acid type A receptor. Proc Natl Acad Sci USA 1992;89:3620–3624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Rothblat LA, Kromer LF. Object recognition memory in the rat: The role of the hippocampus. Behav Brain Res 1991;42:25–32. [DOI] [PubMed] [Google Scholar]
  • 48. Rowlett JK, Tornatzky W, Cook JM, Ma CR, Miczek KA. Zolpidem, triazolam, and diazepam decrease distress vocalizations in mouse pups: Differential antagonism by flumazenil and β‐carboline‐3‐carboxylate‐t‐butyl ester (β‐CCt). J Pharmacol Exp Ther 2001;297:247–253. [PubMed] [Google Scholar]
  • 49. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific γ‐aminobutyric acidA receptor subtypes. Nature 1999;401:796–800. [DOI] [PubMed] [Google Scholar]
  • 50. Sanger DJ. The behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: Increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol 1995;6:116–126. [PubMed] [Google Scholar]
  • 51. Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994;18:355–372. [DOI] [PubMed] [Google Scholar]
  • 52. Sanger DJ, Griebel G, Perrault G, Claustre Y, Schoemaker H. Discriminative stimulus effects of drugs acting at GABAA receptors: Differential profiles and receptor selectivity. Pharmacol Biochem Behav 1999;64:269–273. [DOI] [PubMed] [Google Scholar]
  • 53. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 1996;313:35–42. [DOI] [PubMed] [Google Scholar]
  • 54. Schouenborg J, Kalliomaki J. Functional organization of the nociceptive withdrawal reflexes, I. Activation of hindlimb muscles in the rat. Exp Brain Res 1990;83:67–78. [DOI] [PubMed] [Google Scholar]
  • 55. Thiebot MH. Some evidence for amnesic‐like effects of benzodiazepines in animals. Neurosci Biobehav Rev 1985;9:95–100. [DOI] [PubMed] [Google Scholar]
  • 56. Tobler I, Kopp C, DeBoer T, Rudolph U. Diazepam‐induced changes in sleep: Role of the α1 GABAA receptor subtype. Proc Natl Acad Sci USA 2001;98:6464–6469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Viana MB, Tomaz C, Graeff FG. The elevated T‐maze: A new animal model of anxiety and memory. Pharmacol Biochem Behav 1994;49:549–554. [DOI] [PubMed] [Google Scholar]
  • 58. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti‐anxiety agents. Psychopharmacologia 1971;21:1–7. [DOI] [PubMed] [Google Scholar]
  • 59. Von Voigtlander PF, Lewis RA. A rapid screening method for the assessment of benzodiazepine receptor‐related physical dependence in mice. Evaluation of benzodiazepine‐related agonists and partial agonists. J Pharmacol Meth 1991;26:1–5. [DOI] [PubMed] [Google Scholar]
  • 60. Wafford KA, Whiting PJ, Kemp JA. Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant γ‐aminobutyric acid receptor subtypes. Mol Pharmacol 1993;43:240–244. [PubMed] [Google Scholar]
  • 61. Woods JH, Winger G. Current benzodiazepine issues. Psychopharmacology 1995;118:107–115. [DOI] [PubMed] [Google Scholar]
  • 62. Yasumatsu H, Morimoto Y, Yamamoto Y, et al. The pharmacological properties of Y‐23684, a benzodiazepine receptor partial agonist. Br J Pharmacol 1994;111:1170–1178. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES